A Phase III, multi-center, randomized, double-blind, non-inferiority study of Solithromycin versus Levofloxacin in patients with community-acquired pneumonia
Latest Information Update: 11 Oct 2018
Price :
$35 *
At a glance
- Drugs Solithromycin (Primary) ; Levofloxacin
- Indications Community-acquired pneumonia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors FUJIFILM Toyama Chemical; Toyama Chemical
- 02 Oct 2018 Status changed from active, no longer recruiting to completed.
- 21 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 23 Nov 2016 New trial record